News2021-05-28T14:12:08+00:00
022, 2021

Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform

Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform Its vision restoration technology featured in Nature and New England Journal of Medicine; CiRC is Paragon’s 7 th portfolio company, with more in development Chicago, February 2, 2021 – Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies [...]

1215, 2020

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient has been dosed in its Phase 2 clinical trial evaluating [...]

099, 2020

Jon DeVries Named Qlarity Imaging Chief Executive Officer

Jon DeVries Named Qlarity Imaging Chief Executive Officer Chicago, September 9, 2020 – Life science innovator Paragon Biosciences announced the appointment of Jon T. DeVries as the new chief executive officer of its portfolio company, Qlarity Imaging, a leading artificial intelligence (AI) diagnostics company. A proven leader with in-depth expertise in developing and commercializing medical [...]

091, 2020

Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone

Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone – Half of participants are now enrolled in study evaluating ecopipam (EBS-101) as a potential first-in-class treatment for pediatric patients with Tourette Syndrome – Chicago – September 1, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for [...]

0821, 2020

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares PLYMOUTH MEETING, PA and CHICAGO, IL, August 21, 2020 — Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have [...]

0819, 2020

Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering

Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering PLYMOUTH MEETING, PA and CHICAGO, IL, August 18, 2020 — Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced today the pricing of its upsized initial public offering [...]

Archives
Go to Top